J. Keith Joung is a leading innovator in the field of gene editing. He is the Robert B. Colvin, M.D. Endowed Chair in Pathology, Desmond and Ann Heathwood Research Scholar, and a Pathologist at Massachusetts General Hospital (MGH) and Professor of Pathology at Harvard Medical School. He is also a member of the Center for Cancer Research and the Center for Computational and Integrative Biology at MGH. Dr. Joung has been a pioneer in the development of important technologies for targeted gene editing and epigenetic editing of human cells. He has received numerous awards including an NIH Director’s Pioneer Award, an NIH Director’s Transformative Research Project R01 Award, the MGH Research Scholar Award, an NIH R35 MIRA (Maximizing Investigators Research Award), election into the American Association of University Pathologists, and designation as a “Highly Cited Researcher” in 2016, 2017, 2018, 2019, and 2020 by Thomson Reuters/Clarivate Analytics. He serves on the editorial boards of Genome Biology, Human Gene Therapy, and Trends in Biotechnology. He has co-founded and advises multiple biotechnology companies including Editas Medicine (NASDAQ: EDIT), Beam Therapeutics (NASDAQ: BEAM), Pairwise Plants, SeQure Dx, Inc., and Verve Therapeutics. Dr. Joung holds a Ph.D. in genetics from Harvard University, an M.D. from Harvard Medical School and an A.B. in biochemical sciences from Harvard College.